Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952729 | 1.00 | CCR1 (0.35) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL16110848 | 0.78 | CCR1 (0.38) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL1882667 | 0.78 | NAPRT (0.32) | NAPRT | |
| SCHEMBL29954504 | 0.78 | CCR1 (0.38) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL29957464 | 0.77 | CCR1 (0.37) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL29956615 | 0.76 | CCR1 (0.31) | CCR1CCR5CCR8 | |
| SCHEMBL29952668 | 0.75 | CCR1 (0.35) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL29956787 | 0.75 | NOS2 (0.54) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL15573110 | 0.75 | CCR1 (0.35) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL31016790 | 0.75 | ENPP2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112159421-A | Preparation method of 2-fluoro-4-methyl-3-pyridineboronic acid | 珠海奥博凯生物医药技术有限公司 | 2021-01-01 | — | — | CN | claimed |
| CN-107936048-A | A kind of preparation method of 2 fluorine, 4 methyl, 3 pyridine boronic acid | 珠海奥博凯生物医药技术有限公司 | 2018-04-20 | — | — | CN | claimed |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| CN-110204544-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110256427-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3395818-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021004535-A1 | CINNOLINES AS INHIBITORS OF HPK 1 | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2021-01-14 | — | — | WO | disclosed |
| CN-112159421-A | Preparation method of 2-fluoro-4-methyl-3-pyridineboronic acid | 珠海奥博凯生物医药技术有限公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-112159421-A | Preparation method of 2-fluoro-4-methyl-3-pyridineboronic acid | 珠海奥博凯生物医药技术有限公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-112159421-A | Preparation method of 2-fluoro-4-methyl-3-pyridineboronic acid | 珠海奥博凯生物医药技术有限公司 | 2021-01-01 | — | — | CN | disclosed |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2651899-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012080284-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | CCR1 3157/4885CCR5 2536/4885CCR8 4225/4885 |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | CCR1 836/4885CCR5 554/4885CCR8 1353/4885 |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | CCR1 4302/4885CCR5 3363/4885CCR8 4677/4885 |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | CCR1 4302/4885CCR5 3363/4885CCR8 4677/4885 |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | CCR1 3578/4885CCR5 3046/4885CCR8 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.